Dr. Rashid presented “Adaptive Trial Design for the RAS-Inhibitor Era: Combinations, Resistance, and Biomarker-Guided Therapy” at the NCI GI SPORE Meeting. The talk covered dose optimization for RAS-inhibitor combinations, resistance-aware randomization, and real-time biomarker integration in GI cancer trials. Slides are available here.